Among the company's investments to "transform" its specialty pharmacy services is the opening of a new facility dedicated to cell and gene therapy services.
https://www.cnbc.com/2024/04/25/walgreens-launches-cell-gene-therapies-in-service-expansion.html
Before insurance, Novo Nordisk charges about $1,000 per month for Ozempic in the United States. In Germany, the company charges $59 per month for the same drug.
Wells Fargo believes the company's hyperplasia and depression treatments could each become over $1 billion opportunities.
https://www.cnbc.com/2024/04/24/wells-fargo-becomes-bullish-on-this-biotech-company.html
Alzheimer's drug Leqembi brought in approximately $19 million in sales for the quarter, up from the $10 million the drug generated last year.
https://www.cnbc.com/2024/04/24/biogen-biib-earnings-q1-2024-.html
For the first time, some Medicare beneficiaries will be able to access Novo Nordisk's Wegovy without having to shoulder the total monthly price tag.
Oracle is moving its world headquarters to Nashville, according to Larry Ellison.
https://www.cnbc.com/2024/04/23/oracle-is-moving-its-world-hq-to-nashville.html
Biotech IPOs surged at the start of 2024, but the rest of the year will depend on Fed rate cuts. Meanwhile, doctors using VR and AI to hone their skills.
UnitedHealth Group on Monday said it paid ransom to cyberthreat actors to try and protect patient data.
The rise of family office-style medical practices reflects the surge in wealth and growing demand for hyper-personalized, data-driven health care.
https://www.cnbc.com/2024/04/22/meet-the-private-doctor-to-the-wealthy-at-40000-a-year.html
The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.
23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private.
https://www.cnbc.com/2024/04/18/23andme-ceo-anne-wojcicki-considers-taking-company-private.html
Eli Lilly's Zepbound showed promise to treat obstructive sleep apnea in two late-stage trials. It's yet another reason to stay invested in the drugmaker.
We also love that EPS results on Tuesday came in above the range management had forecasted.
The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit it to the Food and Drug Administration mid-year.
U.S. medication shortages are at a record high so far this year. Meanwhile, UnitedHealth revealed the financial impact of the Change Healthcare cyberattack.
The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic.
https://www.cnbc.com/2024/04/16/johnson-johnson-jnj-earnings-q1-2024.html
UnitedHealth Group announced first-quarter results that beat analysts' expectations for revenue.
https://www.cnbc.com/2024/04/16/unitedhealth-group-unh-q1-2024-earnings.html
Particle Health on Monday said the "vast majority" of its customers are still receiving data from Epic Systems
The financial impact of the Change Healthcare cyberattack is expected to weigh on UnitedHealth Group's first-quarter results.
https://www.cnbc.com/2024/04/15/unitedhealth-q1-results-change-cyberattack-in-focus.html
Epic Systems, the electronic health records giant, cut off its data supply to Particle Health, claiming the startup was using information in unauthorized ways.
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.
Moderna's decision aligns with its broader effort to cut costs by resizing its Covid vaccine-manufacturing footprint.
Seed Health became profitable by selling consumer probiotics, and now it's chasing much bigger science, investing in an AI platform for microbiome moonshots.
Biotech stocks tend to outperform in the months leading up to an interest rate cut. But other factors are driving performance too.
J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai’s approach to AI.
Google Cloud and Bayer are building a new AI-powered platform to help radiologists work more efficiently.
https://www.cnbc.com/2024/04/09/google-partners-with-bayer-on-new-ai-product-for-radiologists.html
Georgia and Arizona rank high for housing, New Mexico for health care, Massachusetts for jobs and Louisiana and Michigan for pension risk.
The interest is due in part to the active and health-conscious lifestyles of Denver residents, local breweries said.
Pfizer plans to file for an expanded approval of Abrysvo, which is currently approved for adults ages 60 and above and expectant mothers.
https://www.cnbc.com/2024/04/09/pfizer-rsv-vaccine-may-protect-high-risk-adults-ages-18-59.html